Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

StrokeTherapy

Financiado

Cerrado

Improving arm and hand function after stroke with clinically relevant delivery o...

Improving arm and hand function after stroke with clinically relevant delivery of neurotrophin 3 to elderly disabled muscles from rats to humans Stroke disables millions worldwide and costs the EU €38 billion each year. Excitingly, my team has identified a clinically-feasible therapy for stroke which reverses disability in rats when given in a clinically-relevant time fram... ver más

31/10/2017

KINGS COLLEGE LOND...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

KINGS COLLEGE LONDON

0.00€ | Lider

Proyectos interesantes

BIO2013-49006-C2-2-R

Medical Technol...

Neurology

127K€ Cerrado

NOGOPROOF

Medical Technol...

Applied Physics

150K€ Cerrado

SAF2008-00737

Medical Technol...

Neuroscience

145K€ Cerrado

REGENERA

Medical Technol...

Biotechnology

150K€ Cerrado

PSI2015-71061-P

Medical Technol...

Neuroscience

52K€ Cerrado

PID2020-119779RB-I00

Medical Technol...

Applied Physics

198K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Stroke disables millions worldwide and costs the EU €38 billion each year. Excitingly, my team has identified a clinically-feasible therapy for stroke which reverses disability in rats when given in a clinically-relevant time frame. Specifically, we have shown that the human growth factor neurotrophin 3 (NT3) promotes locomotor recovery and reverses sensory neglect in adult rats when infused into disabled arm muscles, starting 24 hours after stroke. Importantly, Phase II clinical trials have shown that systemic, repeated high doses of neurotrophin-3 are safe and well-tolerated in humans with other conditions. This paves the way for a Phase II trial in humans after stroke. We now wish to maximise arm and hand (paw) recovery in elderly rats with larger strokes by optimising dose, timing and route. We will then submit for approval a Clinical Trial Application for a randomised, double-blinded, placebo-controlled Phase II human clinical trial to treat stroke using NT3. We also propose multidisciplinary, cutting-edge studies to understand how NT3 promotes plasticity in the brain and spinal cord. 1) We will use wireless neural recording in awake rats and functional brain imaging to study plasticity after stroke and NT3 treatment. 2) Our innovative RatBot will automatically train, rehabilitate and assess grasping of pellet food. 3) To reveal where NT3 is transported we will track a novel tagged version of NT3 in vivo. 4) In an ambitious final study we will maximise recovery of arm and hand function in elderly rats when treatments are delayed by 1 month after larger strokes. In summary, we propose a high-risk, high-yield, transdisciplinary, innovative programme of work to maximise sensory and motor recovery after stroke in elderly rats. Treatment will be initiated in a clinically-relevant time frame (after 24 hours or 1 month) using a clinically-relevant dose and duration of treatment via a clinically-straightforward route, ready for a Phase II clinical trial.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores